ARTICLE | Company News

Pharminox, Cancer Research UK deal

August 16, 2004 7:00 AM UTC

Pharminox received an exclusive 12-month option to license worldwide rights to Phortress and related cancer compounds from Cancer Research Technology Ltd., the technology transfer company of Cancer Research UK. Phortress is the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (5F 203). A U.K. Phase I trial of the compound is ongoing. ...